Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3517-3521

  Song, Ivy ^a   Borland, Julie ^a   Min, Sherene ^a   Lou, Yu ^a   Chen, Shuguang ^a   Patel, Parul ^a   Wajima, Toshihiro ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FLATULENCE; HEADACHE; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; UNPLEASANT DREAM;

ADULT; DRUG INTERACTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RITONAVIR; YOUNG ADULT;

EID: 79959244325     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00073-11     Document Type: Article

References (18)

1. Abel, S., T. M. Jenkins, L. A. Whitlock, C. E. Ridgway, and G. J. Muirhead. 2008. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br. J. Clin. Pharmacol. 65(Suppl. 1):38-46.
2. Anderson, M. S., et al. 2008. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob. Agents Chemother. 52:4228-4232.
3. Arribas, J., et al. 2010. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276), abstr. THLBB205. 18th Int. AIDS Conf.
4. Duval, X., et al. 2000. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob. Agents Chemother. 44:2593.
5. Eron, J., J. Durant, and I. Poizot-Martin. 2010. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961), abstr. MOAB0105. 18th Int. AIDS Conf.
6. Kakuda, T. N., M. Schöller-Gyüre, and R. M. W. Hoetelmans. 2010. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir. Ther. 15:817-829.
7. Lalezari, J., et al. 2009. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naive HIV-1-infected patients, oral presentation TUAB105. Int. AIDS Soc. 5th Conf. HIV Pathogenesis Treatment Prevention.
8. Ménard, A., et al. 2009. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 23:869-871.
9. Min, S., et al. 2010. Pharmacokinetics and safety of S/GSK1349572, a next generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
10. Morse, G. D., et al. 2005. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob. Agents Chemother. 49:3373-3381.
11. Patel, P., et al. 2010. S/GSK1349572, a next generation HIV integrase inhibitor, pharmacokinetics are not affected by omeprazole in healthy adults, abstr. H-934. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.
12. Schafer, J. J., and K. E. Squires. 2010. Integrase inhibitors: a novel class of antiretroviral agents. Ann. Pharmacother. 44:145-156.
13. Song, I., et al. 2009. Evaluation of antacid and multivitamin effects on S/GSK1349572 pharmacokinetics in healthy subjects, abstr. A1-1305. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
14. Song, I., et al. 2010. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation integrase inhibitor, S/GSK1349572, abstr. 616. Abstr. 17th Conf. Retroviruses Opportunistic Infect.
15. Song, I., et al. 2009. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1-infected patients, abstr. WEPEB250. Abstr. Int. AIDS Soc. 5th Conf. HIV Pathogenesis Treatment Prevention.
16. Song, I., et al. 20 May 2010. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J. Clin. Pharmacol. [Epub ahead of print.]
17. Song, I., et al. 2010. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J. Acquir. Immune Defic. Syndr. 55:365-367.
18. Underwood, M., B. Johns, A. Sato, T. Fujiwara, and W. Spreen. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. 5th Int. AIDS Soc. Conf. HIV Pathogenesis Treatment Prevention.